company background image
PGEN

Precigen NasdaqGS:PGEN Stock Report

Last Price

US$1.40

Market Cap

US$290.8m

7D

3.7%

1Y

-79.5%

Updated

24 Jun, 2022

Data

Company Financials +
PGEN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

PGEN Stock Overview

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States.

Precigen Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Precigen
Historical stock prices
Current Share PriceUS$1.40
52 Week HighUS$6.96
52 Week LowUS$1.12
Beta2.43
1 Month Change12.90%
3 Month Change-32.04%
1 Year Change-79.47%
3 Year Change-81.72%
5 Year Change-94.19%
Change since IPO-94.34%

Recent News & Updates

May 12
Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

A week ago, Precigen, Inc. ( NASDAQ:PGEN ) came out with a strong set of quarterly numbers that could potentially lead...

May 10
Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

PGENUS BiotechsUS Market
7D3.7%10.3%6.6%
1Y-79.5%-24.4%-18.5%

Return vs Industry: PGEN underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: PGEN underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is PGEN's price volatile compared to industry and market?
PGEN volatility
PGEN Average Weekly Movement13.2%
Biotechs Industry Average Movement13.0%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: PGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: PGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1998484Helen Sabzevarihttps://www.precigen.com

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium.

Precigen Fundamentals Summary

How do Precigen's earnings and revenue compare to its market cap?
PGEN fundamental statistics
Market CapUS$290.77m
Earnings (TTM)-US$94.17m
Revenue (TTM)US$111.38m

2.6x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PGEN income statement (TTM)
RevenueUS$111.38m
Cost of RevenueUS$112.65m
Gross Profit-US$1.27m
Other ExpensesUS$92.91m
Earnings-US$94.17m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin-1.14%
Net Profit Margin-84.55%
Debt/Equity Ratio272.9%

How did PGEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PGEN?

Other financial metrics that can be useful for relative valuation.

PGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.5x
Enterprise Value/EBITDA-6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PGEN's PS Ratio compare to its peers?

PGEN PS Ratio vs Peers
The above table shows the PS ratio for PGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2622.8x

Price-To-Sales vs Peers: PGEN is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (2622.8x).


Price to Earnings Ratio vs Industry

How does PGEN's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: PGEN is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Biotechs industry average (13.8x)


Price to Sales Ratio vs Fair Ratio

What is PGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PGEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ratio3x

Price-To-Sales vs Fair Ratio: PGEN is good value based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (3x).


Share Price vs Fair Value

What is the Fair Price of PGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PGEN ($1.4) is trading below our estimate of fair value ($17.17)

Significantly Below Fair Value: PGEN is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PGEN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Precigen forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PGEN's revenue (25.7% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: PGEN's revenue (25.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PGEN is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Precigen performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


9.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PGEN is currently unprofitable.

Growing Profit Margin: PGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 9.5% per year.

Accelerating Growth: Unable to compare PGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: PGEN has a negative Return on Equity (-127.54%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Precigen's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PGEN's short term assets ($154.9M) exceed its short term liabilities ($25.6M).

Long Term Liabilities: PGEN's short term assets ($154.9M) do not cover its long term liabilities ($236.1M).


Debt to Equity History and Analysis

Debt Level: PGEN's net debt to equity ratio (121%) is considered high.

Reducing Debt: PGEN's debt to equity ratio has increased from 1.5% to 272.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PGEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PGEN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 2.6% each year.


Discover healthy companies

Dividend

What is Precigen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PGEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PGEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Helen Sabzevari (59 yo)

2.42yrs

Tenure

US$2,516,170

Compensation

Dr. Helen Sabzevari, Ph D., MPH, serves as Independent Director at Kinnate Biopharma Inc. since June 2021. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intrexon Corporation...


CEO Compensation Analysis

Compensation vs Market: Helen's total compensation ($USD2.52M) is above average for companies of similar size in the US market ($USD1.73M).

Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PGEN's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: PGEN's board of directors are seasoned and experienced ( 10.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Precigen, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Precigen, Inc.
  • Ticker: PGEN
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$290.771m
  • Shares outstanding: 207.69m
  • Website: https://www.precigen.com

Number of Employees


Location

  • Precigen, Inc.
  • 20374 Seneca Meadows Parkway
  • Germantown
  • Maryland
  • 20876
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.